therapy
Furthermore, in the FIN-RACo trial (Finnish       Rheumatoid Arthritis Combination Therapy Trial), therapy using a "tailored-steps"       strategy with SSZ (1-2 gm/day), MTX (7.5-1.5 mg/week), hydroxychloroquine (300       mg/day), and Prd (up to 10 mg/day) yielded a significantly increased remission       rate and less peripheral joint damage at two years than the single DMARD       treatment strategy (initially SSZ 2 gm/day), with or without Prd.
Furthermore, in the FIN-RACo trial (Finnish       Rheumatoid Arthritis Combination Therapy Trial),  @SUBJECT$  using a "tailored-steps"       strategy  @PREDICAT$   @OBJECT$  (1-2 gm/day), MTX (7.5-1.5 mg/week), hydroxychloroquine (300       mg/day), and Prd (up to 10 mg/day) yielded a significantly increased remission       rate and less peripheral joint damage at two years than the single DMARD       treatment strategy (initially SSZ 2 gm/day), with or without Prd.